|Day Low/High||21.44 / 22.29|
|52 Wk Low/High||13.67 / 27.80|
Putting cash to work on significant market pullbacks such as the one that occurred Thursday is a key element of the strategy.
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.
These names are displaying both technical and quantitative deterioration.
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
Covered call options provide downside protection for holders of the underlying stock and can yield nice profits, too.
Aggressive traders could go long EXEL on available weakness.
I continue to shuttle new money into the market on declines using buy-write option strategies.
I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.
Trade continues to be listless and in a relatively tight trading range as markets try to end a solid week for investors. Equities are pretty flat across the board. I would not be surprised to see some profit taking later in the day. Cashing in some ...
Here's my strategy which has worked particularly well.
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
These two firms have successful drugs and could make nice additions for larger companies.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Investors are already more focused on what lies ahead when Q1 results start in early April.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
The credit card provider and the biotech concern appear cheap relative to their potential.